4559.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:15):

Stats
Šios dienos apimtis	58 300.00
Vidutinė apimtis	65 303.00
Rinkos kapitalizacija	93.41B
EPS	¥0 ( 2024-01-31 )
Kita pelno data	( ¥0 ) 2024-05-09
Last Dividend	¥22.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	10.81
ATR14	¥1.425 (0.07%)

Tūris Koreliacija

Ilgas: -0.22 (neutral)

Trumpas: 0.48 (neutral)

Signal:(51.893) Neutral

Zeria Pharmaceutical Co., Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Zeria Pharmaceutical Co., Koreliacija - Valiuta/Žaliavos

0.36
( neutral )

0.44
( neutral )

0.84
( strong )

0.71
( moderate )

0.26
( neutral )

-0.44
( neutral )

Zeria Pharmaceutical Co., Finansinės ataskaitos

Annual	2022
Pajamos:	¥68.38B
Bruto pelnas:	¥49.49B (72.37 %)
EPS:	¥140.26

FY	2022
Pajamos:	¥68.38B
Bruto pelnas:	¥49.49B (72.37 %)
EPS:	¥140.26

FY	2022
Pajamos:	¥59.53B
Bruto pelnas:	¥42.15B (70.80 %)
EPS:	¥87.76

FY	2021
Pajamos:	¥55.43B
Bruto pelnas:	¥39.63B (71.50 %)
EPS:	¥67.72

Financial Reports:

No articles found.

Zeria Pharmaceutical Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥18.00 (N/A)	¥0 (N/A)	¥22.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Zeria Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.57 - Stable (11.31%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥7.27	2001-03-27
Last Dividend	¥22.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥532.64	--
Avg. Dividend % Per Year	0.00%	--
Score	3.85	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.57
Div. Directional Score	7.95	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.85

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8016.T	Ex Dividend Junior	2024-02-28	Annually	0.00%
7267.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6498.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
5713.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4530.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
3688.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
3001.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
1861.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9856.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8914.T	Ex Dividend Junior	2023-12-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.116	1.500	7.68	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0564	1.200	8.12	9.74	[0 - 0.3]
returnOnEquityTTM	0.121	1.500	9.77	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.086	0.800	9.57	7.66	[1 - 3]
quickRatioTTM	0.787	0.800	-0.0759	-0.0607	[0.8 - 2.5]
cashRatioTTM	0.350	1.500	9.17	10.00	[0.2 - 2]
debtRatioTTM	0.331	-1.500	4.48	-6.73	[0 - 0.6]
interestCoverageTTM	23.81	1.000	2.29	2.29	[3 - 30]
operatingCashFlowPerShareTTM	313.62	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	313.62	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.646	-1.500	7.42	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.739	1.000	1.016	1.016	[0.2 - 0.8]
operatingProfitMarginTTM	0.133	1.000	9.33	9.33	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.273	1.000	9.60	9.60	[0.2 - 2]
assetTurnoverTTM	0.487	0.800	-0.0854	-0.0683	[0.5 - 2]
Total Score				10.34

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.84	1.000	9.01	0	[1 - 100]
returnOnEquityTTM	0.121	2.50	9.85	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	313.62	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.07	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	313.62	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.378	1.500	-0.811	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.185	1.000	7.87	0	[0.1 - 0.5]
Total Score				5.57

Zeria Pharmaceutical Co.,

Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; sclerosing agent for varicose veins; anti-inflammatory topical blood circulation enhancers; non-steroidal anti-inflammatory ophthalmic solutions; absorbable topical hemostat products; and proton pump inhibitors. In addition, it offers consumer healthcare products, such as nutritional health drugs, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, and food for specified health uses. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.